Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.

Bayer Buys Out BlueRock; Apple, Eli Lilly and Evidation Present First Results from Digital Alzheimer’s Study; 3-V Biosciences Changes Name to Sagimet Biosciences

  • 2019-08-09T19:19:00.000+0000
  • California
  • Author: Lauren Panetta


8/9/19 | GenomeWeb
Illumina Begins Upgrading NIPT Customers to New Version of Test With Genome-Wide Options
https://www.genomeweb.com/sequencing/illumina-begins-upgrading-nipt-customers-new-version-test-genome-wide-options#.XU2mp5NKjUo

8/9/19 | San Diego Union-Tribune
Lassoing Lassa Fever, with an Assist from San Diego Researchers
https://www.sandiegouniontribune.com/business/biotech/story/2019-08-08/lassoing-lassa-fever-with-an-assist-from-san-diego-researchers

8/8/19 | Geron Corporation
Geron: Starts Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes More
http://www.globenewswire.com/news-release/2019/08/08/1899205/0/en/Geron-Starts-Phase-3-Clinical-Trial-in-Lower-Risk-Myelodysplastic-Syndromes.html

8/8/19 | Pfenex
Pfenex: Appointment of New Board Member, Lorianne Masuoka, M.D. More
https://www.globenewswire.com/news-release/2019/08/08/1899601/0/en/Pfenex-Announces-Appointment-of-New-Board-Member-Lorianne-Masuoka-M-D.html

8/8/19 | Xconomy
Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work
https://xconomy.com/boston/2019/08/08/bayer-buys-out-bluerock-betting-at-least-240m-more-on-stem-cell-work/

8/8/19 | FiercePharma
Bayer, Elanco Could Lock Up Animal Health Merger Next Week: Report
https://www.fiercepharma.com/pharma/bayer-set-to-lock-up-animal-health-merger-elanco-next-week-report?mkt_tok=eyJpIjoiTkRneU5UQTBOamt4TnpOaiIsInQiOiJwcmpmaHNzbE5KMU5PSmxNQURtbjFnVFMzTmpadVJrWlwvZU5OR0hqZlhYK1NudnBtRlwvcVwvRWplTEwxOUlBMTNjS2twTThsZDBpeU9CMkJ1ZHVYdW9OYzhwYkNjN1U4V2tYdVwvQU5qdkx1RkZHT2xEMmV3cmlDamFGdFUrQ2tjMTEifQ%3D%3D&mrkid=29867982

8/8/19 | FierceBiotech
Apple, Eli Lilly and Evidation Present First Results from Digital Alzheimer’s Study
https://www.fiercebiotech.com/medtech/apple-eli-lilly-evidation-present-first-results-from-digital-alzheimer-s-study?mkt_tok=eyJpIjoiTVdSaE5HUmxPV1ExWXpjeSIsInQiOiJBWEs4SnZjTHU3NlJRcll3NlJVUHFTaHgrcW1RRG1cL2FUcHptUjBraWJCd3JRRVBrOFNEaGJsNnVTSXM1QktnNVY5TWF0dG50MzhmcUM4RmxQOHY3SEhhYktYaCs1RUhXaTJEQ0tDWlByOFZUU1FMSmpKeGF4WXM1VzZuWkZhUU0ifQ%3D%3D&mrkid=29867982

8/8/19 – UC San Diego
UCSD: Adding MS Drug to Targeted Cancer Therapy May Improve Glioblastoma Outcomes More
https://ucsdnews.ucsd.edu/pressrelease/adding-ms-drug-to-targeted-cancer-therapy-may-improve-glioblastoma-outcomes

8/7/19 | Merck
LYNPARZA® (olaparib) Phase 3 PROfound Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint
https://investors.merck.com/news/press-release-details/2019/LYNPARZA-olaparib-Phase-3-PROfound-Trial-in-HRR-Mutation-Selected-Metastatic-Castration-Resistant-Prostate-Cancer-Met-Primary-Endpoint/default.aspx

8/6/19 | FiercePharma
Regeneron's Sanofi Deal Finally Turns a Profit, Thanks to Dupixent
https://www.fiercepharma.com/pharma/more-than-a-decade-sanofi-and-regeneron-hit-profitability-antibody-partnership?mkt_tok=eyJpIjoiTTJRMVltVXlNMlprTlRjNCIsInQiOiJROThmMks1NUw2WkZydksyRHVSWEpVZGYwM0FoYlllekN6UFJMdjRvbk4zU2txVzdScnJwVFBYOTlKaVE2Z0JyTTFES2lOUG5IZVhCQUk1MWR2aHBLb2dXcDlpbDZNXC9zXC9PejljNHlBSnQ4K3ZWM3NTWHRaSnp4TDQybXpCV2JEIn0%3D&mrkid=29867982

8/5/19 | Sagimet Biosciences
3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing
https://www.prnewswire.com/news-releases/3-v-biosciences-changes-name-to-sagimet-biosciences-and-closes-25-million-financing-300895896.html

8/5/19 | Allakos
Allakos Announces AK002 Met All Prespecified Primary and Secondary Endpoints in Phase 2 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Eosinophilic Gastritis (EG) and/or Eosinophilic Gastroenteritis (EGE)
https://www.globenewswire.com/news-release/2019/08/05/1896758/0/en/Allakos-Announces-AK002-Met-All-Prespecified-Primary-and-Secondary-Endpoints-in-Phase-2-Randomized-Double-Blind-Placebo-Controlled-Study-in-Patients-with-Eosinophilic-Gastritis-EG-.html